Abstracts Archive - Page 20 of 2616 - ACR Meeting Abstracts

Abstract Number: 0185 • ACR Convergence 2025
Promoting Health Services Research Rigor and Reproducibility using CodeMapper: A novel tool for harmonization, collaboration, and precision
Emily Holladay¹, Nick McCormick², Robert Matthews³, Shanette Daigle⁴, Fenglong Xie⁵, Tapan Mehta¹ and Jeffrey Curtis⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Auburn University, Auburn, AL, ³Foundation for Advancing Science Technology Education and Research, Hoover, ⁴Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Medication, procedure, and diagnosis coding using structured data is fundamental to using real-world data to support clinical research, impacting cohort selection, patient recruitment, and…
Abstract Number: 0244 • ACR Convergence 2025
Effectiveness and safety of Anifrolumab in Non-Systemic Cutaneous Lupus
Carmen Lasa Teja¹, Javier Loricera², Marcos López-Hoyos³, Carmen Bejerano-Herreria⁴, Andrea Estébanez⁵, Mireia Sanmartin Martínez⁶, Marta González-Fernández⁷, Ivan Ferraz Amaro⁸ and Ricardo Blanco⁹, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Immunology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁵Department of Dermatology, Hospital Universitario Doctor Peset, Valencia, Spain, Valencia, Spain, ⁶Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ⁷Basurto University Hospital, Bilbao, Pais Vasco, Spain, ⁸Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Anifrolumab is a human monoclonal antibody targeting the type I interferon receptor, approved for the treatment of systemic lupus erythematosus (SLE), with demonstrated efficacy…
Abstract Number: 0128 • ACR Convergence 2025
Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research
Jheel Bhatt¹, Elizabeth Sloan², Selcan Demir³, Mojca Avramovic⁴, Seza Özen⁵, Doruk Erkan⁶ and Tadej Avcin⁷, ¹Advent Health Orlando, Orlando, FL, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³Eskisehir Osmangazi University, Eskişehir, Turkey, ⁴University Children's Hospital, Ljubljana, Slovenia, ⁵Hacettepe University Medical Faculty, Ankara, Turkey, ⁶Hospital for Special Surgery, New York, NY, ⁷University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a rare, thrombo-inflammatory autoimmune disease characterized by thrombosis and nonthrombotic manifestations in patients with persistent positive antiphospholipid antibodies, with…
Abstract Number: 0172 • ACR Convergence 2025
Cancer Screening for Patients with Rheumatic Diseases: A Scoping Review
Teresa Xiao¹, Namrata Singh² and Pankti Reid³, ¹University of Chicago, Chicago, IL, ²University of Washington, Bellevue, WA, ³University of Chicago Medical Center, Chicago, IL
Background/Purpose: There is minimal guidance on specific cancer screening practices for rheumatic diseases (RDs) other than for myositis. The aim of this scoping review was…
Abstract Number: 0240 • ACR Convergence 2025
Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features
Amir Razmjou¹, Alexandra Klomhaus², David Kellner³, Meika Fang⁴, Michael Weisman⁵ and John FitzGerald³, ¹UCLA / Veterans Affairs, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA, Los Angeles, CA, ⁴VA Greater Los Angeles/UCLA, Los Angeles, CA, ⁵Cedars-Sinai Medical Center, LOS ANGELES, CA
Background/Purpose: Behçet’s disease (BD) is a chronic systemic disease with heterogenous clinical presentations. The strongest genetic risk factor and diagnostic biomarker for BD is the…
Abstract Number: 0220 • ACR Convergence 2025
National Implementation of a Medication Safety Dashboard to Improve HLA-B*58:01 Testing Among Allopurinol Users in the Veterans Health Administration
Alissa Becerril¹, Jing Li², Cherish Wilson³, Gary Tarasovsky⁴, Abimbola Fadairo-Azinge⁵, Mary Whooley⁴ and gabriela Schmajuk⁶, ¹UCSF, san francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA, ⁴SFVA, San Francisco, ⁵UCSF, San Francisco, ⁶University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Allopurinol can cause life-threatening severe cutaneous adverse reactions, especially in patients who carry the HLA-B58:01 allele. Because this allele is more common among Southeast…
Abstract Number: 0140 • ACR Convergence 2025
Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study
Sindhuja Rajendran¹, ashish mathew², sukesh chandran nair³, john mathew² and ruchika goel², ¹Christian Medical College ,Vellore, Madurai, Tamil Nadu, India, ²Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ³Christian,Medical College ,Vellore ,India, Vellore, Tamil Nadu, India
Background/Purpose: Non-criteria manifestations occur in 24% in Primary antiphospholipid syndrome (PAPS) . The efficacy of immunosuppressants in patients with above condition is not certain due…
Abstract Number: 0191 • ACR Convergence 2025
Advanced therapy use in RA patients with moderate disease activity in a large NHS Foundation Trust in South London, UK
Aoibhinn Kelly¹, Maddalena Rupnik², Nasra Ahmed¹, Mrinalini Dey³ and Elena Nikiphorou⁴, ¹King's College Hospital NHS Foundation Trust, London, United Kingdom, ²Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴King's College London, London, United Kingdom
Background/Purpose: Moderate disease in rheumatoid arthritis (RA) is defined as a 28-joint disease activity score (DAS28) of 3.2-5.1(MDAS). As per the National Institute for Health…
Abstract Number: 0170 • ACR Convergence 2025
Rheumatoid arthritis, serologic status and risk of heart failure: A national cohort study
Seonyoung Kang¹, Kyungdo Han², Yeonghee Eun³, Jinhyung Jung⁴, Seulkee Lee¹, Hoon-Suk Cha¹, Jaejoon Lee⁵, Seonghye Kim¹, Se Yun Kim⁶, Dong Wook Shin¹ and Hyungjin Kim⁷, ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ²Soongsil University, Seoul, Republic of Korea, ³Kangbuk Samsung Hospital, seoul, Republic of Korea, ⁴Sungkyunkwan University School of Medicine, Suwon, Republic of Korea, ⁵Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁶Sungkyunkwan University, Seoul, Republic of Korea, ⁷Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Although rheumatoid arthritis (RA) is a known risk factor for heart failure (HF), a limited number of studies has explored the association based on…
Abstract Number: 0148 • ACR Convergence 2025
Air Pollution as a Trigger for Flares in Chronic Inflammatory Rheumatic Diseases: a Prospective Single-Center Study in the South of France
Coralie Cruzel¹, antonio Iannelli², Alexandre Armengaud³, Sonia Oppo³, Marie Charlotte Trojani⁴, Stephanie Ferrero⁴, Veronique Breuil⁴, Eric Fontas⁵, Christian Roux⁴ and Clément Viala⁴, ¹². Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, France, France, ²³. Centre Hospitalier Universitaire de Nice-Digestive Surgery and Liver Transplantation Unit, Archet ² Hospital, ⁰⁶²⁰² Nice, France., NIce, France, ³¹. University Cote d’Azur, Rheumatology department, CHU Nice, France, Marseille, France, ⁴¹. University Cote d’Azur, Rheumatology department, CHU Nice, France, NIce, France, ⁵². Department of Clinical Research, Cimiez Hospital, CHU Nice, Université Côte d'Azur, Nice, France, NIce, France
Background/Purpose: Rheumatoid arthritis (RA) and spondyloarthritis (SpA), are chronic inflammatory rheumatic diseases. Despite significant advancements in their management through novel therapies, some patients continue to…
Abstract Number: 0157 • ACR Convergence 2025
Influence of Outpatient Clinic Visits on Receipt of the COVID-19 Vaccine among People with Autoimmune Rheumatic Diseases
Lesley Jackson¹, Nicole Wright², Rahima Begum³, Fazlur Rahman¹, Rena Patel¹, Kenneth Saag⁴, Jeffrey Curtis⁵ and Maria I. ("Maio") Danila⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Tulane University School of Medicine, New Orleans, LA, ³University of Alabama at Birmingham, Birmingham, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁶University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Rheumatologists and primary care providers (PCPs) are some of the most trusted clinicians for people living with autoimmune rheumatic diseases (AIRD), and they may…
Abstract Number: 0155 • ACR Convergence 2025
Effect Modification of Cigarette Smoking on the Relationship between Post Traumatic Stress Disorder and Rheumatoid Arthritis Risk
Kelsey Coziahr¹, Harlan Sayles¹, Tate Johnson¹, Joshua Baker², Punyasha Roul³, Grant Cannon⁴, Gary Kunkel⁵, Bryant England¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³UNMC, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Post-traumatic stress disorder (PTSD) is associated with increased systemic inflammation that may increase the risk of developing autoimmune disorders such as rheumatoid arthritis (RA).…
Abstract Number: 0225 • ACR Convergence 2025
Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses
Juan Schmukler¹, Tengfei Li² and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: Comorbid anxiety (ANX), depression (DEP), and fibromyalgia(FM) are reported as more common in patients with rheumatoid arthritis (RA) and other rheumatic diagnoses than in…
Abstract Number: 0181 • ACR Convergence 2025
Launch of the National Tele-Rheumatology Program (NTRP) to Expand Rheumatology Care to Rural Veterans
Cherish Wilson¹, Catherine Nasrallah², Gary Tarasovsky³, Alicia Hamblin⁴, Asia Williams⁵, Broderick Flynn⁵, Bernard Ng⁶ and gabriela Schmajuk⁷, ¹UCSF / SFVA, San Francisco, CA, ²University of California San Francisco (UCSF), San Francisco, CA, ³SFVA, San Francisco, ⁴UCSF, San Francisco, CA, ⁵Lexington VA, Lexington, ⁶Lexington VA, University of Washington, Seattle, ⁷University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Given the nationwide shortage of rheumatologists, particularly in rural areas, many Veterans Affairs (VA) facilities have struggled to hire or retain specialists, resulting in…
Abstract Number: 0129 • ACR Convergence 2025
Analysis of Antiphosphatidylserine/prothrombin Antibodies as a Predictor of Lupus Anticoagulant in the Pediatric Population
Jonathan Marilao¹, Sean Yates² and Elizabeth Sloan³, ¹University of Texas Southwestern, Dallas, TX, ²University of Texas Southwestern, Dallas, ³UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic thromboinflammatory autoimmune disease characterized by thrombotic or obstetric events occurring in individuals with persistently positive antiphospholipid antibodies (aPL).…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].